936571-58-3

Upstream product

• 619-45-4 4-methoxycarbonyl aniline 
• 660-88-8 5-aminopentanoic acid 
• 152120-54-2 N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 
• 212567-95-8 N,N'-bis-tert-butoxycarbonyl-5-guanidino-pentanoic acid 

Downstream Products

• 936571-60-7 4-{(tert-butoxycarbamoyl-methyl)-[5-(N,N'-bis-tert-butoxycarbonyl)guanidino-pentanoyl]amino}-benzoic acid methyl ester 
• 936571-77-6 2(S)-(2(S)-{4-[(tert-butylcarbamoyl-methyl)-(5-guanidino-pentanoyl)-amino]benzoylamino}-3-methyl-butyrylamino)-3-phenyl-propionic acid 
• 936571-76-5 2(S)-(2(S)-{4-[carboxymethyl-(5-guanidino-pentanoyl)-amino]benzoylamino}-3-methyl-butyrylamino)-3-phenyl-propionic acid 
• 1032374-61-0 C₂₉H₄₅N₅O₈ 
• 1032374-60-9 C₂₉H₄₄N₄O₉ 
• 936571-59-4 4-{tert-butoxycarbonylmethyl-[5-(N,N'-bis-tert-butoxycarbonyl)guanidino-pentanoyl]amino}-benzoic acid methyl ester 

Relevant academic research and scientific papers

SUBSTRATE-MIMETIC AKT INHIBITOR

Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with 0 a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionallv homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterpartsand are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.

Modifications of the GSK3β substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics

Amplification, overexpression, and elevated activation of Akt have been detected in many human malignancies making it an important target for cancer therapy. The Akt substrate-binding site offers a large number of potential interactions to an appropriatel